FDA gives Lupin's generic Eliquis tentative approval
Lupin has received tentative approval from the Food and Drug Administration for generic Eliquis tablets (apixaban tablets). The generic will be available in 2.5-mg and 5-mg dosage strengths.
Lupin's generic Eliquis is indicated for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation; prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism following hip or knee replacement surgery; and treatment of deep vein thrombosis and pulmonary embolism, as well as reducing risk of both events recurring.
The product had a market value of roughly $6.4 billion according to September 2018 IQVIA data.
Lupin's generic Eliquis is indicated for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation; prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism following hip or knee replacement surgery; and treatment of deep vein thrombosis and pulmonary embolism, as well as reducing risk of both events recurring.
The product had a market value of roughly $6.4 billion according to September 2018 IQVIA data.